Optimizing Stroke and Bleeding Risk Assessment in Patients with Atrial Fibrillation : A Balance of Evidence, Practicality and Precision by M. Proietti et al.
Optimizing Stroke and Bleeding Risk Assessment
in Patients with Atrial Fibrillation: A Balance of
Evidence, Practicality and Precision
Marco Proietti1,2 Nebojsa Mujovic3,4 Tatjana S. Potpara3,4
1 Istituto di Ricerche Farmacologiche “Mario Negri” IRCCS, Milan, Italy
2Department of Internal Medicine and Medical Specialties, Sapienza
University of Rome, Rome, Italy
3School of Medicine, University of Belgrade, Belgrade, Serbia
4Cardiology Clinic, Clinical Centre of Serbia, University of Belgrade,
Belgrade, Serbia
Thromb Haemost
Address for correspondence Tatjana S. Potpara, MD, PhD, Cardiology
Clinic, Clinical Centre of Serbia, Visegradska 26, 11000 Belgrade,
Serbia (e-mail: tatjana.potpara@med.bg.ac.rs).
Optimal stroke prevention using oral anticoagulant (OAC)
therapy is essential for themanagement of patientswith atrial
fibrillation (AF)whoareat increased riskof stroke, butdecision
making on thromboprophylaxis requires evaluation of indivi-
dual patient’s thromboembolic and bleeding risks.1 Several
risk assessment tools have been developed to streamline the
evaluation of patients with AF but navigating through the
labyrinth of options may be confusing for clinicians.2
Stroke Risk in AF: Evidence versus Practical
Decision Making
In this issue of Thrombosis Haemostasis, Borre et al3 reported
a comprehensive systematic review and meta-analysis com-
missioned by the Patient-Centred Outcomes Research Insti-
tute to update a 2013 Agency for Healthcare Research and
Quality review4 of the comparative accuracy and impact on
clinical decision making of several thromboembolic and
bleeding risk assessment tools in patients with AF.
They addressed two key topics: (1) the comparative
diagnostic accuracy and impact on clinical decision making
of available clinical and imaging tools and associated risk
factors for predicting thromboembolic risk; and (2) the
comparative diagnostic accuracy and impact on clinical
decision making of clinical tools and associated risk factors
for predicting bleeding events. The authors conducted an
extensive literature search (from 2000 to 2018) and evidence
appraisal of published data for clinical stroke scores
(CHADS2, CHA2DS2-VASc, Framingham and age, biomarkers
and clinical history [ABC]-stroke), cardiac imaging predictors
and clinical bleeding risk scores (HAS-BLED, HEMOR-
R2HAGES, ATRIA, Bleeding Risk Index and ABC-bleeding).
Not surprisingly, the CHADS2 and CHA2DS2-VASc scores
were the most commonly evaluated stroke risk assessment
tools (29 and 24 studies, respectively). Overall, the CHADS2,
CHA2DS2-VASc and ABC-stroke scores had the best evidence
for prediction ability for stroke—however, notwithstanding
the heterogeneity among studies included in the meta-
analyses, the CHADS2, CHA2DS2-VASc, Framingham and
ABC-stroke scores all had a modest prediction ability for
thromboembolic events, with c-statistic values ranging from
0.63 (Framingham) to 0.69 (continuous CHADS2 score).3 This
is in line with previous meta-analyses5–8 showing broadly
similar performance of various clinical risk factor-based
stroke scores (including the CHA2DS2-VASc) in prediction
of thromboembolic events. However, the difference of the
CHA2DS2-VASc in comparison to other stroke scores is its
relative accuracy in identifying AF patients at truly low riskof
stroke (i.e. CHA2DS2-VASc of 0 in men, or 1 in women) who
do not need any anti-thrombotic therapy.8–10
Recognizing that all clinical scores only have modest
predictive value for high-risk patients that sustain events
and that current risk scores are designed to be simple and
reductionist, the use of a simplified, clinical risk factor-based
approach to the management of AF-related stroke risk has
been acknowledged by recent international AF guide-
lines.1,11 The default should be to ‘offer stroke prevention,
unless the patient is “low risk”’. A simple message is needed,
as guideline-adherent treatment has been associated with
improved outcomes in multiple AF cohorts.12–16
The presence of even a single CHA2DS2-VASc risk factor is
associatedwith an excess in stroke andmortality,17,18 and OAC
use isassociatedwithpositivenetclinicalbenefit incomparison
to aspirin (which is harmful) or no therapy.19 Variations in
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reported event rates for patients’ single-risk-factor AF cohorts
have caused debate20 but may reflect different study settings
(hospitalvs. community), not all risk factors carrying equal risk,
methodological errors (with some papers ‘conditioning on the
future’ by excluding patients who had ever started OAC even
during follow-up) and the inclusion of females (who have 1
point, yet low risk) in reports of event rateswithCHA2DS2-VASc
score of 1.16,21 Indeed, female sex is rather a risk modifier than
an independent stroke risk factor and becomes relevant only in
the presence of other CHA2DS2-VASc factors22; however, ignor-
ing female sex (i.e. using the CHA2DS2-VA score, without ‘Sc’23)
could under-estimate stroke risk in females with AF.24
As mentioned, clinical risk factor-based scores generally
have a modest prediction ability for the outcome event of
interest. Adding various biomarkers (‘biological markers’) to
clinical scores—that is, blood biomarkers (e.g. brain natriure-
tic peptide, cardiac troponin, creatinine, etc.), cardiac or
cerebral imaging (echocardiographic, magnetic resonance,
etc.) or electrocardiographic indices in sinus rhythm (e.g., the
P wave axis25)—improve the score’s prediction ability, at
least statistically, but such complexity may be impractical or
unfeasible outside a highly structured setting.2
Vascular Disease and Stroke Risk
Optimal acknowledgment of clinical information pertaining
to specific CHA2DS2-VASc score component is crucial for
proper stroke risk assessment in each patient. For example,
the ‘V’ (vascular disease) traditionally includes validated
factors such as previous myocardial infarction, complex
aortic plaque or peripheral artery disease.
In this same issue of Thrombosis Haemostasis, Steensig
et al26 extend their recent report on significant association
between the presence of angiographically documented cor-
onary artery disease (CAD) and subsequent thromboembolic
events27 showing that the extent of CAD (i.e. 1-, 2-, 3-vessel
or diffuse) did not add additional risk prediction information
regarding ischaemic stroke, transient ischaemic attack or
systemic embolism among 12,690 AF patients undergoing
coronary angiography (with CAD diagnosed in 59.4%) over a
3-year follow-up. Hence, angiographically documented CAD
should be included in the ‘V’ component of the CHA2DS2-
VASc score. This would translate to an indication for OAC use
in 3% of low-risk patients according to the European AF
guidelines, or in 6% per the U.S. guidelines. Non-invasively
diagnosed CAD using contrast angiography or stress testing
would probably have the same significance, albeit not inves-
tigated in the present study.
Bleeding Risk Assessment
Bleeding risk assessment is a sensitive part of risk evaluation
in AF patients that is sometimes misinterpreted or even
abused.28 All international AF guidelines recommend bleed-
ing risk assessment but beyond listing the bleeding risk
factors, practical guidance on clinical decision making on
Fig. 1 The Atrial fibrillation Better Care (ABC) pathway. NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; TTR, time
in therapeutic range; VKA, vitamin K antagonist.
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OAC use in high-risk AF patients at increased risk of bleeding
is less well specified.1
In their systematic review and evidence appraisal, Borre
et al3 also explored 38 studies that reported on bleeding
risk in AF patients. Overall, they found moderate strength
of evidence on increased bleeding risk in AF patients with
chronic kidney disease, and that the HAS-BLED score
provided the best prediction of bleeding events among
the investigated bleeding risk assessment tools. Indeed, the
HAS-BLED score has been extensively validated in various
setting, including AF patients on OAC (either vitamin K
antagonists [VKA] or non-VKA OACs), aspirin or no anti-
thrombotic therapy, with respect to various bleeding out-
comes (i.e. major bleeding or intracranial haemorrhage).28
Bleeding risk assessment using the HAS-BLED score is not
meant to preclude the use of OAC, but to identify high-risk
patients in whom modifiable bleeding risk factors such as
uncontrolled hypertension (H), labile international normal-
ized ratios in patient taking VKAs (L), concomitant use of
non-steroidal anti-inflammatory drugs, anti-platelet drugs
or excessive alcohol consumption (D) can be addressed or
modified, andwho need clinical follow-up earlier rather than
later (e.g. 4 weeks rather than 4–6 months). Importantly,
using a formal bleeding risk assessment tool (i.e. the HAS-
BLED score) had significantly better predictive value for
bleeding risk assessment comparedwith the approach based
only on modifiable bleeding risk factors.29–31
The Dynamic Nature of Stroke and Bleeding
Risk
Many studies of risk factors and biomarkers have investi-
gated something at study entry (‘baseline’) and ascertained
outcomes many years later (sometimes 5 or 10 years). The
patient’s clinical risk profile changes over time and this
change has been shown to have better prediction ability
for the respective risk than simply relying on the baseline
score values.32,33Hence, neither thromboembolic nor bleed-
ing risks are static and must be re-assessed regularly. This is
part of a comprehensive and holistic approach to the man-
agement of patients with AF34 (see ►Fig. 1).
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